459 results about "Enzymatic synthesis" patented technology

The present invention comprises methods and compositions for splint-assisted enzymatic synthesis of polyribonucleotides using an RNA polymerizing enzyme. The invention provides ligating ribonucleotides comprising ligating a donor RNA molecule to an acceptor RNA molecule in the presence of RNA ligase and a splint, wherein the donor RNA molecule is comprised of at least one nucleotide and a ligation linker moiety, the acceptor RNA molecule is comprised of at least one nucleotide and a ligation linker moiety and the splint is comprised of a polyribonucleotide. The invention also provides splints for use in splint-assisted enzymatic synthesis using an RNA polymerizing enzyme.

Methods for the synthesis of CCI-779 and proline-CCI-779 are described, including a method involving lipase-catalyzed acetylation of 42-hydroxy of rapamycin with a vinyl ester of 2,2-bis(hydroxymethyl) propionic acid in an organic solvent followed by deprotection. Also provided are products containing proline-CCI-779 and uses thereof.

The present invention relates to the enzymatic synthesis of oligosaccharides, including sialylated product saccharides. In particular, it relates to the use of recombinant cells to take up low cost precursors such as glucose, pyruvate and N-actyl-glucosamine, and to synthesize activated sugar moieties that are used in oligosaccharide synthesis. The methods make possible the synthesis of many oligosaccharides using microorganisms and readily available, relatively inexpensive starting materials.

A novel UDP-Gal regeneration process and its combined use with a galactosyltransferase to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

The present invention provides methods for producing sialyloligosaccharides in situ in dairy sources and cheese processing waste streams, prior to, during, or after processing of the dairy source during the cheese manufacturing process. The methods of the present invention use the catalytic activity of alpha(2-3) trans-sialidases to exploit the high concentrations of lactose and alpha(2-3) sialosides which naturally occur in dairy sources and cheese processing waste streams to drive the enzymatic synthesis of alpha(2-3) sialyllactose. alpha(2-3) sialyloligosaccharides produced according to these methods are additionally encompassed by the present invention. The invention also provides for recovery of the sialyloligosaccharides produced by these methods. The invention further provides a method for producing alpha(2-3) sialyllactose. The invention additionally provides a method of enriching for alpha(2-3) sialyllactose in milk using transgenic mammals that express an alpha(2-3) trans-sialidase transgene. The invention also provides for recovery of the sialyllactose contained in the milk produced by this transgenic mammal either before or after processing of the milk. Transgenic mammals containing an alpha(2-3) trans-sialidase encoding sequence operably linked to a regulatory sequence of a gene expressed in mammary tissue are also provided by the invention.

Disclosed is a dietary ingredient comprising at least one edible lipid which does not inhibit mineral absorption, enhances mineral absorption and intake, particularly a chemically or enzymatically synthesized synthetic oil, particularly glyceride-based lipid with high levels of mono- or polyunsaturated fatty acids at positions sn-1 and sn-3 of the glycerol backbone, vegetable- and plant-derived oil, such as flax and canola oils, short and medium chains lipid, preferably MCT and an oil mimicking the triglyceride composition of human mother's milk fat and its various uses.The dietary ingredient is particularly intended for use in enhancing calcium absorption and in the prevention and / or treatment of disorders associated with depletion of bone calcium and bone density, prevention and treatment of osteoporosis, for the enhancement of bone formation and bone mass maximization and for the enhancement of bone formation in infants and young children.

Poly(amine-co-ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the nanoparticles are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.

Methods for the synthesis of CCI-779 and proline-CCI-779 are described, including a method involving lipase-catalyzed acetylation of 42-hydroxy of rapamycin with a vinyl ester of 2,2-bis(hydroxymethyl) propionic acid in an organic solvent followed by deprotection. Also provided are products containing proline-CCI-779 and uses thereof.

The invention relates to a preparation method of sterol ester and in particular relates to an enzymatic synthesis method of phytosterol ester / phytostanol ester by utilizing ultrasonic enhancement. The method is characterized by comprising the following steps: 1) preparing a heterogeneous enzyme reaction system: weighing the phytosterol ester / phytostanol ester and fatty acid at a molar ratio of 1:(1.2-2), adding a reaction solvent, and adding enzyme and a molecular sieve; 2) performing enzymatic esterification with ultrasonic assistance: immersing an ultrasonic probe in a reaction solution, opening an ultrasonic wave generator, constantly radiating with ultrasonic wave for 0.5 to 3 hours under mechanical stirring, and continuously reacting for 4 to 10 hours under mechanical stirring after the radiation is completed; and 3) removing the fatty acid with ultrasonic assisted saponification to obtain the product. According to the method, the enzymatic esterification reaction time can be remarkably shortened, the usage of enzyme can be reduced, and the saponification speed of excessive fatty acid can be accelerated, so that the efficiency of separation and purification can be improved, and the obtained phytosterol ester / phytostanol ester product has the characteristics of light color, high purity and safety without contamination.

Process for enzymatically synthesizing carboxylic esters, characterized in that mixing and discharge of the water of reaction are effected by introducing a gas while achieving low effectiveness ratios EV.

The invention provides methods for purifying carbohydrates, including oligosaccharides, nucleotide sugars, and related compounds, by use of ultrafiltration, nanofiltration and / or reverse osmosis. The carbohydrates are purified away from undesired contaminants such as compounds present in reaction mixtures following enzymatic synthesis or degradation of oligosaccharides.

This invention discloses an improved enzymatic process, under organic solvent free conditions, for the incorporation of fatty acids such as omega-3 fatty acids into phospholipids. The rate of transesterification is increased 4 times by adding a base to the reaction mixture, typically an amine. The invention also discloses novel phospholipid compositions as well as novel use of the phospholipid compositions as a food supplement, a fish feed, animal feed and human food. In addition to methods for enriching prey organisms used in aquaculture, methods of reducing arachidonic acid levels in mammalian plasma / red blood cells and methods for increasing DHA levels in the mammalian brain.

Dietary supplements for treating a neurotransmitter deficiency include one or more precursors of the deficient neurotransmitter and a cofactor for activating in vivo enzymatic synthesis of the deficient neurotransmitter. The dietary supplements can also include an appropriate neurotransmitter, such as an amino acid. When administered through the oral mucosa, increases in levels of the deficient neurotransmitters and relief from deficiency symptoms are obtained.